Table 1.
Demographic and clinical characteristics of RA patients and CS
| Characteristics | CS (n = 7) | Early RA (n = 14) | Chronic RA (n = 14) | Untreated RA (n = 7) | P |
|---|---|---|---|---|---|
| Sex (Male/Female) | 1/6 | 0/14 | 1/13 | 2/5 | .2048 |
| Age (yr)a | 46.6 ± 17.7 | 37.1 ± 13.2 | 56.6 ± 13.6 | 35.9 ± 8.5 | .0040 |
| Disease duration (yr)a | NA | 0.7 ± 0.2 | 16.4 ± 9.6 | 6.2 ± 11.1 | <.0001 |
| Leukocytes (mil/mm3)a | 7.4 ± 2.3 | 7.4 ± 2.0 | 6.7 ± 1.4 | 10.1 ± 2.7 | .0466 |
| Plaquets (mm3)a | 282.2 ± 79.8 | 363.6 ± 73.4 | 298.1 ± 58.0 | 436.5 ± 132.0 | .0166 |
| ESR (mm/h)a | 15.0 ± 7.6 | 33.5 ± 16.5 | 35.1 ± 13.3 | 28.0 ± 16.6 | .1066 |
| CRP (mg/dL)a | 4.±3.2 | 8.2 ± 7.3 | 7.6 ± 5.1 | 17.9 ± 13.0 | .0372 |
| RF (UI/mL)a | 7.4 ± 0.5 | 480.6 ± 579.8 | 163.4 ± 282.8 | 186.3 ± 228.9 | .0007 |
| Anti‐CCP (U/mL)a | 1.6 ± 0.01 | 139.4 ± 147.9 | 125.6 ± 103.6 | 66.7 ± 114.3 | .0012 |
| DAS28a | ‐ | 4.3 ± 1.7 | 4.5 ± 1.7 | 5.1 ± 0.86 | .614 |
| NSAIDs b | 12 (85.7%) | 12 (85.7%) | 4 (57.14%) | ||
| Prednisoneb | ‐ | 4 (28.57%) | 0 (0%) | 0 (0%) | |
| DMARDS b | |||||
| Sulfasalazineb | ‐ | 9 (64.28%) | 8 (57.14%) | 0 (0%) | |
| Chloroquineb | ‐ | 12 (85.7%) | 9 (64.28%) | 0 (0%) | |
| Methotrexateb | ‐ | 12 (85.7%) | 14 (100%) | 0 (0%) |
Values are mean ± SD.
Abbreviations: anti‐CCP, anti‐cyclic citrullinated peptide; CRP, C‐reactive protein; CS, control subjects; ESR, erythrocyte sedimentation rate; NA, not applicable; RA, rheumatoid arthritis; RF, rheumatoid factor; yr, year.
a
= mean ± SD.
b
= n (%).